
Opinion|Videos|July 18, 2024
Future of TROP2- and HER2-Directed ADCs in Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What do you envision for the role of ADCs in the future treatment of HER-negative and HER2-low metastatic breast cancer?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5







































